Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
07:30am, Tuesday, 17'th Sep 2024
Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancer Companies will jointly research DNA-damage response kinase targets
Applied DNA Launches Mpox Clade I and Clade II Testing Service
09:00am, Wednesday, 11'th Sep 2024
STONY BROOK, NY / ACCESSWIRE / September 11, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical labor
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
07:50am, Thursday, 05'th Sep 2024
Ginkgo Bioworks hopes to revolutionize many industries with bioengineered products. Its business, however, remains deeply unprofitable.
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA
09:00am, Wednesday, 04'th Sep 2024
OAKLAND, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following an
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
09:00am, Wednesday, 04'th Sep 2024
- Pilot Project To Demonstrate Effectiveness of CertainT® for Cotton Textile Traceability - STONY BROOK, NY / ACCESSWIRE / September 4, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA),
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock
08:45am, Tuesday, 03'rd Sep 2024
Ginkgo Bioworks isn't yet profitable, so it's running on a finite amount of cash. Cutting expenses may actually cause the company to lose out on revenue.
3 Stocks Hitting New 52-Week Lows. Should You Back Up the Truck?
07:23am, Tuesday, 03'rd Sep 2024
Dumpster diving can be a lucrative pastime. One man's trash is another's treasure.
This 1 AI Stock Could Revolutionize Biotech and Pharma
05:11am, Monday, 02'nd Sep 2024
Ginkgo Bioworks seeks to create a high-throughput biopharma services platform. So far, that platform isn't profitable, but it can still generate a lot of scientific data.
Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
07:00am, Friday, 30'th Aug 2024
BOSTON , Aug. 30, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Off
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
10:25am, Thursday, 29'th Aug 2024
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
From Promise to Peril: The Downfall of Ginkgo Bioworks
11:51am, Monday, 26'th Aug 2024
“Our revenue has grown substantially, and we are proud of the progress we've made in establishing strategic partnerships. The robust pipeline of projects we have in place positions us well for conti
Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?
10:11am, Saturday, 24'th Aug 2024
Ginkgo Bioworks is still not anywhere close to being operationally profitable. Management isn't planning on it becoming profitable anytime soon.
Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?
01:19pm, Friday, 23'rd Aug 2024
Applied DNA Sciences, Inc. APDN stock traded higher on Friday on a strong session volume of 114.23 million, compared to the average volume of 6.78 million, according to data from Benzinga Pro.
-Validation Studies Confirmed the Assay Can Detect Mpox Clade I and Clade Ib in addition to Clade II- STONY BROOK, NY / ACCESSWIRE / August 23, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Co
Ginkgo Bioworks: Here Comes The Test
10:31pm, Wednesday, 21'st Aug 2024
Ginkgo Bioworks has struggled with missed revenue targets, leading to a significant decline in share value. The recent Q2 report showed a 30% decrease in total revenues, with cost structure still a ma
